骨痨敌联合化学治疗初治菌阳肺结核临床观察  

作　　者：石淑萍[1] 林元敏[1] 钟小林[1] 

机构地区：[1]隆昌县疾病预防控制中心,四川内江642150

出　　处：《中外医疗》2010年第32期5-5,7,共2页China & Foreign Medical Treatment

摘　　要：目的评价骨痨敌注射液治疗初治菌阳肺结核的临床疗效。方法 128例初治菌阳肺结核患者,随机分为2组,均采用2HRZE(S)/4HR方案治疗。A组加用骨痨敌治疗,观察治疗后肺部病灶吸收,痰菌阴转情况。结果治疗1～8周痰菌阴转率A组显著高于B组,(P<0.05),治疗2～6个月痰菌阴转率A组与B组无明显差异,(P>0.05);疗程结束时胸部病灶显著吸收率:A、B2组分别为87.5%和73.4%,空洞闭合率A、B2组分别为84.4%和67.2%,2组比较存在显著差异。结论骨痨敌注射液联合化学治疗初治菌阳肺结核患者能提高痰菌转阴率,促进肺部病灶吸收,其副作用低,作为中药制剂使用安全,值得临床使用。Objective To evaluate the clinical efficacy of GULAODI injector being used to cure sputum positive tuberculosis.Methods 128 firstly-treaded bacillus-positive tuberculisis patients are divided into groups A and B.They are treated by the cure of 2HRZE/4HR.Group A adds GLD to treat to observe the efficacy of the changes of lesions absorption and sputum bacteriological conversion on the latter-half lung.Results Sputum negative conversion rates of Group A is sharply higher than that of Group B after 1-8weeks of（P0.05）;Sputum negative conversion rates of Group A is a little different from that of Group B after 2～6 months weeks（P0.05）;As for the absolute lesion absorbing at the end of the cure,Group A is 87.5% while Group B is 73.4%.As with the cavities closing,Group A is 84.4% while Group B is 67.2%.The two groups has significant difference.Conclusion To cure firstly-treated culture-positive tuberculosis the GLD injector with chemotherapy can higher the sputum negative conversion and improve the lesion absorption.It has low side-effect and safe to use as a kind of traditional Chinese medicine product.It is well worthwhile in clinical trertment.

关 键 词：肺结核 骨痨敌 疗效 

分 类 号：R521[医药卫生—内科学]